Gene

SLC29A1

solute carrier family 29 member 1 (Augustine blood group)

Explore in graph →CI-GENE-00031144HGNC:11003 ENSG00000112759 NCBI 2030 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
SLC29A1 Overexpression1
Gemcitabine	Pancreatic Adenocarcinoma	Predictive	B	Supports Sensitivity Response	4	accepted	EID10145 Surgically resected PDACs were used to create tissue microarrays, which were scored for antibody staining of hENT1 (SLC29A1). For patients treated with gemcitabine (n=243), high levels of hENT1 were a… (full text at CIViC) PMID 22705007 · Maréchal et al., 2012 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (2)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved2 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Thymoma (TCGA GDC, 2025) thym_tcga_gdc	Thymoma	Ssm	2	121	1.7%	110	cbioportal

Literature

Linked publications (1)

25 per page, newest first.

pubmedPublishedShowing 1–1 of 1 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.
· Gastroenterology · 2012 · PMID 22705007 · validated civic_curation pubmed